glp 1 drug made by eli lilly Why is suddenly pulling ahead in the GLP-1 weight-loss race Eli Lilly to seek approval

PMC 13000015

When will biosimilar competition meaningfully impact pricing

Microdosing may not produce the same level of weight loss seen with standard dosing, and outcomes depend on individual factors and medical oversight

Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8

Raufman about Gila monster (Heloderma) venom